WO2009089975A1 - Food composition - Google Patents
Food composition Download PDFInfo
- Publication number
- WO2009089975A1 WO2009089975A1 PCT/EP2008/067537 EP2008067537W WO2009089975A1 WO 2009089975 A1 WO2009089975 A1 WO 2009089975A1 EP 2008067537 W EP2008067537 W EP 2008067537W WO 2009089975 A1 WO2009089975 A1 WO 2009089975A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polyphenols
- liquid food
- food product
- product according
- red
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/60—Drinks from legumes, e.g. lupine drinks
- A23L11/65—Soy drinks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention relates to a food composition, specifically to a functional food composition having one or more health effects in humans.
- a health effect is related to a decreased risk of cardiovascular disorders.
- polyphenols Polyphenolic compounds
- Polyphenols enjoy a considerable scientific interest for their health promoting properties.
- Epidemiological studies have shown that consumption of foods rich in polyphenols is associated with a lower incidence of cardiovascular disorders.
- polyphenols are widespread among plants and plant products, polyphenols are naturally present in many foods including fruits, vegetables and fruit drinks, in varying amounts .
- red grape products such as red grape juice and red wine.
- the paradox is the low cardiovascular mortality rate observed in Mediterranean populations in association with red wine consumption despite a high saturated fat intake.
- Grape juice and red wine are less suitable, since in juice and wine the concentration of polyphenols is relatively low. Also, when juice or red wine are added to a functional food composition, there may be product components introduced into the food that are not desirable, such as alcohol and sugar.
- the extracts include grape extract, wine extract, skin- and/or seed extract. However most of these extracts are not suitable for application in a functional food, since they are not efficacious or have a bad taste.
- EP-B-930831 describes a plant-derived flavonol-containing dry composition obtained from grapes, wine or flavonol-containing by-products or waste-products of wine making having a high polyphenol content, preferably at least 45% polyphenols.
- the dry composition is suitable for reducing the risk of cardiovascular disease.
- the composition has the effect of inhibiting oxidation of plasma LDL, stimulation of TGF- ⁇ production, inhibiting platelet aggregation and stimulating fibrinolysis.
- the dry composition is used as a medicament or as food supplement.
- FR 2772235 describes polyphenol compositions comprising a concentrated grape juice (comprising 1-20 wt% of polyphenols) , wine extract (comprising 1-20 wt% of polyphenols) and a hydrosoluble olive extract comprising 0.5 to 40 wt% of polyphenols .
- WO2005/122793 discloses a fruit juice product comprising a combination of grape juice extract and wine extract.
- Anonymous: "Boisson au soja enrichi en calcium, XP002471959 retrieved from the internet 2008-03-07 discloses a soy product comprising grape-seed extract in an undisclosed amount.
- a problem with the addition of polyphenols to food products is that often the taste of the product is negatively affected.
- food products containing polyphenols may negatively interact with the bioavailability of the polyphenol ingredients, therewith reducing its effectiveness as a health promoting food product.
- the invention in a first aspect relates to a liquid food product comprising 0.1 to 1.5 wt% of polyphenols, wherein said polyphenols contain a mixture of polyphenols from red grape and polyphenols from red wine in a weight ratio of from 1:1 to 1: 5, said food product comprising 0.1 to 5 wt% of soyprotein.
- the product comprises 0.2 to 1.4 wt%, preferably 0.4 to 1.2 wt% and , more preferably 0.6- 1.0 wt% of polyphenols which are a combination of polyphenols from red grape juice and polyphenols from red wine in a polyphenol weight ratio of from 1:1 to 1:5, more preferred from 1:1.5 to 1:3, most preferred from 1:1.8 to 1:2.5, based on the values obtained from the Folin-Ciocalteu method.
- compositions of the invention are liquid food products.
- liquid food products are fluid products with a relatively low viscosity, which can readily be poured and which can easily be consumed as a drink. Such products can easily be manufactured, packed and dosed to consumers.
- Preferred liquid food products of the invention are packed in closed containers comprising single dose portions of 50 to 250 ml, for example from 75 to 125 ml.
- single dose portions are separately packed in closed containers e.g. bottles to ensure reliable dosing of ingredients while maintaining optimal freshness of the product.
- the total amount of polyphenols per single dose portion is from 100 to 1500 mg, more preferred from 400 to 1300 mg, especially preferably from 600 to 1000 mg.
- the liquid products of the invention comprise from 0.1% to 5 wt% of soy protein more preferably from 0.5 to 4 wt%, for example from 2.5 to 4.5 wt%, more general from 3.0 to 4.0 wt%. These levels can readily be obtained by using a soy-based drink as the basis for the liquid food product of the invention. Typically a soy-based drink is readily available e.g. containing about 3.5 wt% of soy protein. The level of soy-based drink in the liquid product preferably is from 75 to 99.9%, more preferred from 80 to 95 wt%.
- the liquid products of the invention comprise a fruit juice base whereto soy protein has been added, for example orange juice or apple juice with soy protein.
- Such fruit juice base which can for example be a mixture of concentrated juice and water or can be undiluted fruit juice, is advantageously present in amounts from 75 to 99.9%, more preferred from 80 to 95 wt% wherein these amounts are calculated as if undiluted, non-concentrated fruit juice is used.
- Liquid products of the invention preferably comprise from 0.2- 1.4 wt% of polyphenols, more preferred from 0.4 to 1.2 wt%, more preferred from 0.6 to 1.0 wt%.
- the polyphenol content can for example be determined by measuring the gallic acid equivalent value as illustrated in the examples, but other suitable methods e.g. via spectroscopy are readily available.
- the liquid food products of the invention are substantially free from the milk protein casein.
- the amount of casein from dairy sources such as dairy bovine milk protein is zero or less than 1 wt%, more preferred less than 0.5 wt%, especially 0.1 wt% or lower. More preferred the liquid food products of the invention are substantially free from milk protein.
- At least part of the polyphenols originates from a red wine extract having a high polyphenol content.
- a red wine extract having a high polyphenol content examples of preferred red wine extracts that are commercially available, are given in table 1.
- At least part of the polyphenols originates from a red grape juice extract having a high polyphenol content.
- red grape juice extracts that are commercially available, are given in table 2.
- the food composition according to the invention may preferably be used as a physiologically functional food product.
- the consumption of the food composition by a human subject is effective in causing in the human subject one or more, preferably two or more, more preferably three or more and most preferably all four of the following effects: a) reduction of hypertension; b) inhibition of platelet aggregation; c) reduction of level of total blood cholesterol; d) reduction of level of LDL cholesterol.
- the liquid food products according to the invention may comprise common food ingredients in addition to the polyphenols, such as water, flavour, sugar, fruits, minerals, vitamins, stabilisers, thickeners, starches etc. in appropriate amounts.
- the liquid food products are soy-based products or fruit juice based products.
- the liquid food product of the invention can advantageously be used as a dietary component especially for consumers with a wish to decrease cardiovascular risk, such as high cholesterol levels or increased blood pressure. Especially advantageously the food product is for use to lower blood pressure.
- the dosing of the food product preferably is such that a daily dosage contains 600 to 1200 mg, especially 700 to 1000 mg of polyphenols.
- a daily dosage is administered in a single dose from a closed container comprising 600 to 1200 mg, particularly 700 to 1000 mg of polyphenols.
- the intake of the daily dose is part of a meal. More preferably the daily dosage is consumed as part of a main meal, particularly breakfast, wherein preferably the overall intake of milk protein during said meal is less than 5 g, more preferred from 0 to 3 g.
- Total polyphenol content can be measured using Folin-Ciocalteau colour reagent at mildly basic pH in an UV-spectroscopic method. Quantification can be achieved by determining the total polyphenol content as Gallic Acid Equivalents (GAE) or epicatechin equivalents (ECE) , using standard curves for gallic acid and epicatechin.
- GAE Gallic Acid Equivalents
- ECE epicatechin equivalents
- the trial consisted of 5 consecutive treatment periods which were identical except for the test product consumed. Five treatments using products A to E as described below were subsequently tested in a randomised order according to the following schedule. Day 1 to 4 : subjects consumed the test product during breakfast .
- Day 5 subjects consumed test product at the test facility in a fasted state. Starting on day 2 in the evening and up to and including day 5 after the last blood sample was collected the subjects were on a low polyphenol diet including restrictions on alcohol and fish consumption.
- the measurements consisted of 24 hours urine collection, whereby the hippuric acid content in the total urine is determined.
- Urinary hippuric acid is believed to be a good marker to measure the bioavailability of polyphenols and its metabolites in the human body, whereby an increased hippuric acid content is believed to co-incide with a lowering of the blood pressure.
- Treatment A daily dosis of gelatine capsules containing 550 mg red wine polyphenols (source provinols, ex Seppic) and 250 mg of red grape polyphenols (source Meganatural, Rubired grape extract ex Polyphenolics) .
- the daily dose was administered with 200 ml water as part of a breakfast and the last dose in a fasted state.
- Treatment B dosing of polyphenols in a dairy base: 550 mg red wine polyphenols and 250 mg of red grape polyphenols (as above) were added to 200 ml of yoghurt in a closed container containing 1.4 wt% of fat, 3.4% of milk protein and 0.7 wt% lactic acid.
- the daily dose was administered as part of a breakfast and the last dose in a fasted state.
- Treatment C (dosing of polyphenols in a soy-based drink base) : 550 mg red wine polyphenols and 250 mg of red grape polyphenols as above were added to 200 ml of a soy-based drink, with a protein content of 3.4% and a fat level of 2 wt% . the daily dosis was administered as part of a breakfast and the last dose in a fasted state.
- Treatment D (dosing of polyphenols in a orange juice base) : 550 mg red wine polyphenols and 250 mg of red grape polyphenols as above were added to 200ml of a juice with a carbohydrate content of 4 wt% which is substantially protein free. The daily dose was administered as part of a breakfast and the last dose in a fasted state.
- Treatment E (placebo) empty gelatine capsules containing no red wine polyphenols and no grape juice polyphenols. Administered as part of breakfast and the last dose in a fasted state.
- Treatment E lead to a base line hippuric acid content in urine collected over 24 hours of 0.89 g.
- Treatment A lead to a hippuric acid content of 1.27 g amounting to an increase in the hippuric acid content (compared to the placebo) of 0.38 g/24 h.
- Treatment B lead to a hippuric acid content of 1.14 amounting to an increase in hippuric acid content compared to the placebo of 0.25 g/24 h.
- Overall the increase of hippuric acid in Treatment B compared to the placebo was 34% less than the increase while using Treatment A.
- Treatment C lead to a hippuric acid content of 1.26 g amounting to an increase in the hippuric acid content (compared to the placebo) of 0.37 g/24 h. This is a similar increase in hippuric acid as treatment A, showing that soy is an excellent vehicle for the dosage of these polyphenolic compounds.
- Treatment D lead to a hippuric acid content of 1.19 g. Amounting to an increase in hippuric acid (compared to the placebo) of 0.30. Overall the increase in hippuric acid content in treatment D compared to the placebo was 21% less than the increase while using treatment A.
- a weight ratio of 1:2.2 of red grape to red wine polyphenols provided in a liquid food provide significant increases in hippuric acid content compared to the placebo.
- soy protein unexpectedly does not negatively impact the hippuric acid content in the urine.
- the presence of dairy protein leads to a considerable lowering of the hippuric acid content compared to the soy base and the positive control.
- hippuric acid content of 0.25 g or more is an increase sufficient to have an impact on the blood pressure of the consumer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Agronomy & Crop Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A liquid food product comprising 0.1 to 1.5 wt% of polyphenols, wherein said polyphenols contain a mixture of polyphenols from red grape and polyphenols from red wine in a weight ratio of from 1:1 to 1:5, closed container comprising 50 to 250 ml of the liquid food product and use of the liquid food product for reducing blood pressure.
Description
Food composition
Field of the invention
The invention relates to a food composition, specifically to a functional food composition having one or more health effects in humans. In particular, such health effect is related to a decreased risk of cardiovascular disorders.
Background to the invention Polyphenolic compounds (hereinafter polyphenols) enjoy a considerable scientific interest for their health promoting properties. Epidemiological studies have shown that consumption of foods rich in polyphenols is associated with a lower incidence of cardiovascular disorders.
Since polyphenols are widespread among plants and plant products, polyphenols are naturally present in many foods including fruits, vegetables and fruit drinks, in varying amounts .
A number of studies in the prior art were directed to red grape products, such as red grape juice and red wine.
Well-known is the so-called λFrench paradox' . The paradox is the low cardiovascular mortality rate observed in Mediterranean populations in association with red wine consumption despite a high saturated fat intake.
Effects of grape products on various cardiovascular health markers, including blood pressure, platelet function and plasma lipid profiles, have been evaluated in a number of human trials, see for example the overview as given in WO2005/122793.
For the application in functional food products, grape juice and red wine are less suitable, since in juice and wine the concentration of polyphenols is relatively low. Also, when juice or red wine are added to a functional food composition, there may be product components introduced into the food that are not desirable, such as alcohol and sugar.
Dozens of different grape and wine extracts are commercially available, the extracts include grape extract, wine extract, skin- and/or seed extract. However most of these extracts are not suitable for application in a functional food, since they are not efficacious or have a bad taste.
EP-B-930831 describes a plant-derived flavonol-containing dry composition obtained from grapes, wine or flavonol-containing by-products or waste-products of wine making having a high polyphenol content, preferably at least 45% polyphenols. The dry composition is suitable for reducing the risk of cardiovascular disease. In particular, the composition has the effect of inhibiting oxidation of plasma LDL, stimulation of TGF-β production, inhibiting platelet aggregation and stimulating fibrinolysis. The dry composition is used as a medicament or as food supplement.
FR 2772235 describes polyphenol compositions comprising a concentrated grape juice (comprising 1-20 wt% of polyphenols) , wine extract (comprising 1-20 wt% of polyphenols) and a hydrosoluble olive extract comprising 0.5 to 40 wt% of polyphenols .
WO2005/122793 discloses a fruit juice product comprising a combination of grape juice extract and wine extract.
Anonymous: "Boisson au soja enrichi en calcium, XP002471959 retrieved from the internet 2008-03-07 discloses a soy product comprising grape-seed extract in an undisclosed amount.
A problem with the addition of polyphenols to food products is that often the taste of the product is negatively affected. On the other hand food products containing polyphenols may negatively interact with the bioavailability of the polyphenol ingredients, therewith reducing its effectiveness as a health promoting food product.
It is therefore an object of the present invention to provide a food product which can easily be dosed in adequate amounts, wherein the food product comprises polyphenol components and wherein the type of food and the type and amount of polyphenols is chosen such that good food product quality can be obtained while ensuring a good bioavailability of the polyphenol compounds and which is adequately efficacious in decreasing risk of cardiovascular disorders, specifically reduction of hypertension, inhibition of platelet aggregation, reduction of level of total blood cholesterol and/or reduction of level of LDL cholesterol.
It is a further object of the present invention to provide a useful alternative polyphenol comprising food product.
One or more of these objects are attained according to the invention in a food composition as described below.
In a first aspect the invention relates to a liquid food product comprising 0.1 to 1.5 wt% of polyphenols, wherein said polyphenols contain a mixture of polyphenols from red grape and
polyphenols from red wine in a weight ratio of from 1:1 to 1: 5, said food product comprising 0.1 to 5 wt% of soyprotein.
Surprisingly it has been found that a combination of red grape and red wine polyphenols, preferably on relatively high amounts, in liquid food products comprising 0.1 to 5 wt% of soy protein provides food products with good polyphenol bioavailability which can easily be dosed.
Advantageously the product comprises 0.2 to 1.4 wt%, preferably 0.4 to 1.2 wt% and , more preferably 0.6- 1.0 wt% of polyphenols which are a combination of polyphenols from red grape juice and polyphenols from red wine in a polyphenol weight ratio of from 1:1 to 1:5, more preferred from 1:1.5 to 1:3, most preferred from 1:1.8 to 1:2.5, based on the values obtained from the Folin-Ciocalteu method.
Detailed description of the invention
Compositions of the invention are liquid food products. For the purpose of the invention liquid food products are fluid products with a relatively low viscosity, which can readily be poured and which can easily be consumed as a drink. Such products can easily be manufactured, packed and dosed to consumers. Preferred liquid food products of the invention are packed in closed containers comprising single dose portions of 50 to 250 ml, for example from 75 to 125 ml. Preferably single dose portions are separately packed in closed containers e.g. bottles to ensure reliable dosing of ingredients while maintaining optimal freshness of the product. Advantageously the total amount of polyphenols per single dose portion is from 100 to 1500 mg, more preferred from 400 to 1300 mg, especially preferably from 600 to 1000 mg.
The liquid products of the invention comprise from 0.1% to 5 wt% of soy protein more preferably from 0.5 to 4 wt%, for example from 2.5 to 4.5 wt%, more general from 3.0 to 4.0 wt%. These levels can readily be obtained by using a soy-based drink as the basis for the liquid food product of the invention. Typically a soy-based drink is readily available e.g. containing about 3.5 wt% of soy protein. The level of soy-based drink in the liquid product preferably is from 75 to 99.9%, more preferred from 80 to 95 wt%. Alternatively the liquid products of the invention comprise a fruit juice base whereto soy protein has been added, for example orange juice or apple juice with soy protein. Such fruit juice base, which can for example be a mixture of concentrated juice and water or can be undiluted fruit juice, is advantageously present in amounts from 75 to 99.9%, more preferred from 80 to 95 wt% wherein these amounts are calculated as if undiluted, non-concentrated fruit juice is used.
Liquid products of the invention preferably comprise from 0.2- 1.4 wt% of polyphenols, more preferred from 0.4 to 1.2 wt%, more preferred from 0.6 to 1.0 wt%. For this purpose the polyphenol content can for example be determined by measuring the gallic acid equivalent value as illustrated in the examples, but other suitable methods e.g. via spectroscopy are readily available.
In a preferred embodiment, the liquid food products of the invention are substantially free from the milk protein casein. For the purpose of the invention this means that the amount of casein from dairy sources such as dairy bovine milk protein is zero or less than 1 wt%, more preferred less than 0.5 wt%, especially 0.1 wt% or lower. More preferred the liquid food products of the invention are substantially free from milk
protein. These low levels of milk proteins ensure that minimum interference between the polyphenols and the milk protein, therewith optimizing the bioavailability of the polyphenols.
Preferably at least part of the polyphenols originates from a red wine extract having a high polyphenol content. Examples of preferred red wine extracts that are commercially available, are given in table 1.
Table 1: Preferred, commercially available wine extracts
Preferably at least part of the polyphenols originates from a red grape juice extract having a high polyphenol content. Examples of preferred red grape juice extracts, that are commercially available, are given in table 2.
Table 2: Preferred, commercially available red grape juice extracts
The food composition according to the invention may preferably be used as a physiologically functional food product. According to a preferred embodiment, the consumption of the food composition by a human subject is effective in causing in the human subject one or more, preferably two or more, more preferably three or more and most preferably all four of the following effects: a) reduction of hypertension; b) inhibition of platelet aggregation; c) reduction of level of total blood cholesterol; d) reduction of level of LDL cholesterol.
The liquid food products according to the invention may comprise common food ingredients in addition to the polyphenols, such as water, flavour, sugar, fruits, minerals, vitamins, stabilisers, thickeners, starches etc. in appropriate amounts. Preferably the liquid food products are soy-based products or fruit juice based products.
The liquid food product of the invention can advantageously be used as a dietary component especially for consumers with a wish to decrease cardiovascular risk, such as high cholesterol levels or increased blood pressure. Especially advantageously the food product is for use to lower blood pressure.
The dosing of the food product preferably is such that a daily dosage contains 600 to 1200 mg, especially 700 to 1000 mg of polyphenols. Especially the daily dosage is administered in a single dose from a closed container comprising 600 to 1200 mg, particularly 700 to 1000 mg of polyphenols. Especially preferable the intake of the daily dose is part of a meal. More preferably the daily dosage is consumed as part of a main meal, particularly breakfast, wherein preferably the overall intake of milk protein during said meal is less than 5 g, more preferred from 0 to 3 g.
Examples
Determination of polyphenol content
Total polyphenol content can be measured using Folin-Ciocalteau colour reagent at mildly basic pH in an UV-spectroscopic method. Quantification can be achieved by determining the total polyphenol content as Gallic Acid Equivalents (GAE) or epicatechin equivalents (ECE) , using standard curves for gallic acid and epicatechin.
Example 1
Polyphenol containing products were tested as follows:
Thirty-five apparently healthy males age between 18 and 70 years and a Body Mass Index between 19 and 30 kg/m2 took part in the present study.
Time Schedule of human trial
The trial consisted of 5 consecutive treatment periods which were identical except for the test product consumed. Five treatments using products A to E as described below were subsequently tested in a randomised order according to the following schedule.
Day 1 to 4 : subjects consumed the test product during breakfast .
Day 5: subjects consumed test product at the test facility in a fasted state. Starting on day 2 in the evening and up to and including day 5 after the last blood sample was collected the subjects were on a low polyphenol diet including restrictions on alcohol and fish consumption.
During breakfast no milk products were consumed. Blood was collected on day 5 before consumption of the test product and after 1, 2 and 3 hours.
Urine was collected starting on day 4 after breakfast for 24 hours .
A wash out period was observed on days 6 and 7. After the wash out period a new product was tested.
After the fifth treatment period no wash out period was observed.
The measurements consisted of 24 hours urine collection, whereby the hippuric acid content in the total urine is determined.
Urinary hippuric acid is believed to be a good marker to measure the bioavailability of polyphenols and its metabolites in the human body, whereby an increased hippuric acid content is believed to co-incide with a lowering of the blood pressure.
Treatments A-E
Treatment A (positive control) : daily dosis of gelatine capsules containing 550 mg red wine polyphenols (source provinols, ex Seppic) and 250 mg of red grape polyphenols (source Meganatural, Rubired grape extract ex Polyphenolics) . The daily dose was administered with 200 ml water as part of a breakfast and the last dose in a fasted state.
Treatment B (dosing of polyphenols in a dairy base) : 550 mg red wine polyphenols and 250 mg of red grape polyphenols (as above) were added to 200 ml of yoghurt in a closed container containing 1.4 wt% of fat, 3.4% of milk protein and 0.7 wt% lactic acid. The daily dose was administered as part of a breakfast and the last dose in a fasted state.
Treatment C (dosing of polyphenols in a soy-based drink base) : 550 mg red wine polyphenols and 250 mg of red grape polyphenols as above were added to 200 ml of a soy-based drink, with a protein content of 3.4% and a fat level of 2 wt% . the daily dosis was administered as part of a breakfast and the last dose in a fasted state.
Treatment D (dosing of polyphenols in a orange juice base) : 550 mg red wine polyphenols and 250 mg of red grape polyphenols as above were added to 200ml of a juice with a carbohydrate content of 4 wt% which is substantially protein free. The daily dose was administered as part of a breakfast and the last dose in a fasted state.
Treatment E (placebo) empty gelatine capsules containing no red wine polyphenols and no grape juice polyphenols. Administered as part of breakfast and the last dose in a fasted state.
The following results were obtained
Treatment E lead to a base line hippuric acid content in urine collected over 24 hours of 0.89 g.
Treatment A lead to a hippuric acid content of 1.27 g amounting to an increase in the hippuric acid content (compared to the placebo) of 0.38 g/24 h.
Treatment B lead to a hippuric acid content of 1.14 amounting to an increase in hippuric acid content compared to the placebo of 0.25 g/24 h. Overall the increase of hippuric acid in Treatment B compared to the placebo was 34% less than the increase while using Treatment A.
Treatment C lead to a hippuric acid content of 1.26 g amounting to an increase in the hippuric acid content (compared to the placebo) of 0.37 g/24 h. This is a similar increase in hippuric acid as treatment A, showing that soy is an excellent vehicle for the dosage of these polyphenolic compounds.
Treatment D lead to a hippuric acid content of 1.19 g. Amounting to an increase in hippuric acid (compared to the placebo) of 0.30. Overall the increase in hippuric acid content in treatment D compared to the placebo was 21% less than the increase while using treatment A.
Summary of results
Increase in hippuric acid content compared to placebo (g/24 h) A 0.38
B 0.25
C 0.37
D 0.30
E - -
These results show the following:
* The use of relatively high levels of polyphenols provide an increase in hippuric acid content for all liquid food bases.
* A weight ratio of 1:2.2 of red grape to red wine polyphenols provided in a liquid food provide significant increases in hippuric acid content compared to the placebo.
* The presence of soy protein unexpectedly does not negatively impact the hippuric acid content in the urine.
* The presence of dairy protein leads to a considerable lowering of the hippuric acid content compared to the soy base and the positive control.
* The use of a liquid juice as the base for administering polyphenols leads to a reduction of hippuric acid content compared to the soy base and the positive control. However, surprisingly the use of a liquid juice in combination with relatively high levels of polyhenols wherein the weight ratio of red grape polyphenols to red wine polyphenols is 1:2.2 still provides an adequately high increase of hippuric acid levels in the blood, as maybe deduced from the high urinary hippuric acid content .
In this context it is submitted that an increase of hippuric acid content of 0.25 g or more (24 h/urine as compared to placebo) is an increase sufficient to have an impact on the blood pressure of the consumer.
Claims
1. A liquid food product comprising 0.1 to 1.5 wt% of polyphenols, wherein said polyphenols contain a mixture of polyphenols from red grape and polyphenols from red wine in a weight ratio of from 1:1 to 1:5 and 0.1 to 5 wt% of soy protein.
2. Liquid food product according to claim 1, comprising 0.2 to 1.4 wt%, preferably 0.4 to 1.2 wt% and more preferably 0.6 to 1.0 wt% of said polyphenols.
3. Liquid food product according to claim 1 or 2, wherein the polyphenols contain polyphenols from red grape and polyphenols from red wine in a weight ratio of from 1:1 to 1:3.
4. Liquid food product according to any one of claims 1 to 3 comprising 0.1 to 5 wt% of soy protein.
5. Liquid food product according to any one of claims 1 to 3 comprising 75 to 99.9 wt% of fruit juice.
6. Liquid food product according to any one of claims 1 to 5 comprising no or less than 1 wt% of casein, preferably comprising no or less than 1 wt% of milk protein .
7. Liquid food product according to any one of claims 1 to 6 packed in closed container comprising 50 to 250 ml of the liquid food product.
8. Liquid food product according to claim 7, wherein the closed container comprises 75 to 125 ml of the liquid food product.
9. Liquid food according to claim 7 or 8 comprising per single dose 100 to 1500 mg, preferably 400 to 1300 mg and even more preferably 800 to 1100 mg of polyphenols.
10. Use of the liquid food product according to any one of claims 1 to 9 for reducing blood pressure.
11. Use according to claim 10, wherein the use involves the daily consumption of a single dose in accordance to claim 7, 8 or 9.
12. Use according to claim 11, wherein the consumption takes place as part of a meal, preferably breakfast.
13. Use according to claim 12, wherein said meal provides an overall intake of less than 5 gram, more preferred 0 to 3 gram of milk protein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08150339.3 | 2008-01-17 | ||
| EP08150339 | 2008-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009089975A1 true WO2009089975A1 (en) | 2009-07-23 |
Family
ID=39135135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2008/067537 Ceased WO2009089975A1 (en) | 2008-01-17 | 2008-12-15 | Food composition |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20090186119A1 (en) |
| WO (1) | WO2009089975A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2698696A1 (en) * | 2007-09-07 | 2009-03-12 | Wilkes And Associates, Inc. | Non-alcoholic wine beverage |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1356689A (en) * | 1970-12-17 | 1974-06-12 | Calpis Food Ind Co Ltd | Method of manufacturing a fruit beverage |
| FR2772235A1 (en) * | 1997-12-12 | 1999-06-18 | Fabre Pierre Sante | POLYPHENOLIC COMPOSITION, USEFUL AS A FOOD SUPPLEMENT, NUTRACEUTICAL OR COSMETIC COMPOSITION |
| EP0930831A1 (en) * | 1996-09-20 | 1999-07-28 | The Howard Foundation | Flavonol containing food supplements |
| WO2005122793A1 (en) * | 2004-06-18 | 2005-12-29 | Unilever N.V. | Food composition with wine extract and grape juice extract |
| DE202006002700U1 (en) * | 2006-02-17 | 2006-05-11 | Benediktus Kräuterlabor Strathausen GmbH | Composition, useful as a food supplement, comprises olive leaf extract, pomegranate extract, red wine and/or grape extract and vitamin extract |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1443946A2 (en) * | 2001-07-03 | 2004-08-11 | Nutri Pharma ASA | Composition comprising soy and use thereof in the prevention and/or treatment of various diseases |
| US20040022877A1 (en) * | 2002-07-30 | 2004-02-05 | Nancy Green | Cardiovascular health enhancement with soy fortified orange juice compositions |
| HUE025620T2 (en) * | 2005-09-28 | 2016-04-28 | Constellation Brands Inc | Grape extract, dietary supplement thereof, and processes therefor |
-
2008
- 2008-12-15 WO PCT/EP2008/067537 patent/WO2009089975A1/en not_active Ceased
-
2009
- 2009-01-15 US US12/321,069 patent/US20090186119A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1356689A (en) * | 1970-12-17 | 1974-06-12 | Calpis Food Ind Co Ltd | Method of manufacturing a fruit beverage |
| EP0930831A1 (en) * | 1996-09-20 | 1999-07-28 | The Howard Foundation | Flavonol containing food supplements |
| FR2772235A1 (en) * | 1997-12-12 | 1999-06-18 | Fabre Pierre Sante | POLYPHENOLIC COMPOSITION, USEFUL AS A FOOD SUPPLEMENT, NUTRACEUTICAL OR COSMETIC COMPOSITION |
| WO2005122793A1 (en) * | 2004-06-18 | 2005-12-29 | Unilever N.V. | Food composition with wine extract and grape juice extract |
| DE202006002700U1 (en) * | 2006-02-17 | 2006-05-11 | Benediktus Kräuterlabor Strathausen GmbH | Composition, useful as a food supplement, comprises olive leaf extract, pomegranate extract, red wine and/or grape extract and vitamin extract |
Non-Patent Citations (3)
| Title |
|---|
| "What is the ultimate OPC+ ?", INTERNET CITATION, 2003, XP002301604, Retrieved from the Internet <URL:http://www.health-diets-and-weight-loss.com/find_out_more/antioxidant s/ultimateops.htm> [retrieved on 20041020] * |
| ANONYMOUS: "Boisson au soja enrichi en calcium", 2008, XP002471959, Retrieved from the Internet <URL:http://ooshop.com> [retrieved on 20080307] * |
| WIEL VAN DE A: "[Nutrition and health--favorable effect of wine and wine flavonoids on cardiovascular diseases]", MEDLINE, 21 December 2002 (2002-12-21), XP002301608 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090186119A1 (en) | 2009-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102458155B (en) | Green tea extract with improved bioavailability | |
| US11564952B2 (en) | Water-soluble and water-insoluble propolis products with high antioxidant capacity and their production methods | |
| WO2005095573A1 (en) | Alcoholic dring containing maca extract | |
| CN110876258B (en) | Beetroot juice for improving intestinal absorption rate, its preparation method and application | |
| JP5888574B1 (en) | Blood flow improver | |
| JP6000521B2 (en) | Antihypertensive agent | |
| Ansari et al. | Fortification of food and beverages with phytonutrients. | |
| JP2009062301A (en) | Yaeyama Aoki Extract and its Use | |
| Ahmed et al. | Effect of adding pomegranate (Punica granatum) juice and seed extract on the physicochemical, rheological and sensory properties of ice cream | |
| US20090186119A1 (en) | Food composition | |
| AU2006308219B2 (en) | Food composition | |
| US20090186118A1 (en) | Food composition | |
| JP2023029502A (en) | Blood flow improver | |
| JP6841444B2 (en) | Immunostimulant | |
| EP3681311A1 (en) | Process and formulation of powdered sweet lime fruit juice with enhanced real fruit content and stability | |
| RU2220615C1 (en) | Biologically active product | |
| JP2019001763A (en) | Blood cholesterol rise inhibitory composition | |
| JP2018000157A (en) | Ferulic acid-containing beverage | |
| JP7562169B2 (en) | Composition for suppressing elevation of blood cholesterol | |
| KR20090037048A (en) | Beverage composition using lemon concentrate and preparation method thereof | |
| RU2683539C2 (en) | Beverage based on the milk whey (variants) | |
| Ebabhamiegbebho et al. | Nutritional quality assessment of Pinasoy: a pineapple and soybean blend drink | |
| RU2078520C1 (en) | Taste and aromatic additive for food products | |
| JP6838752B2 (en) | Blood flow improving composition | |
| JP6934150B2 (en) | Oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08871091 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08871091 Country of ref document: EP Kind code of ref document: A1 |


